Efficacy of Spravato® on TRD

The efficacy of Spravato in treating TRD has been shown in clinical trials. Results showed that Spravato, in combination with an oral antidepressant, was effective in reducing symptoms of depression in individuals with TRD. In one study, approximately half of the participants achieved a significant reduction in depression symptoms after two weeks of treatment with Spravato.

It's important to note that while Spravato can be an effective treatment option for some individuals with TRD, it is not a cure and results may vary. It is also not recommended for everyone and its use should be carefully monitored by a healthcare professional due to its potential side effects and potential for abuse. As with any medication, it's crucial to have an open and honest conversation with your doctor about the benefits and risks of treatment with Spravato.

Spravato (Esketamine) is a nasal spray medication approved for treatment-resistant depression (TRD). It works by rapidly increasing the levels of the neurotransmitter glutamate in the brain, which is thought to help reduce depression symptoms. Spravato is used in combination with an oral antidepressant and is administered under medical supervision in a clinical setting. It is not a first-line treatment for depression and is only recommended for individuals who have not responded to other treatments. Common side effects of Spravato include headache, nausea, dizziness, and disassociation.